

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
**(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.  
**SDF 02-8**

In Re Application Of: **Okubo et al.**


Serial No.  
**10/069,087**

Filing Date  
**May 3, 2002**

Examiner  
**Micah Paul Young**

Group Art Unit  
**1615**

Title: **Medicinal Compositions for Oral Use**



Address to:

**Assistant Commissioner for Patents**  
**Washington, D.C. 20231**

**37 CFR 1.97(b)**

1. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☒ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☒ the statement specified in 37 CFR 1.97(e);

**OR**

☐ the fee set forth in 37 CFR 1.17(p).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
SDF 02-8

In Re Application: **Okubo et al.**

Serial No.  
10/069,087

Filing Date  
May 3, 2002

Examiner  
Micah Paul Young

Group Art Unit  
1615

Medicinal Compositions for Oral Use



**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☐ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. \_\_\_\_\_ as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☐ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F

\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited  
April 14, 2004 with the U.S. Postal Service  
as first class mail under 37 C.F.R. 1.8 and is  
addressed to the Assistant Commissioner for Patents,  
Washington, D.C. 20231.

  
Signature of Person Mailing Correspondence

Stuart D. Frenkel

\_\_\_\_\_  
Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

  
Signature

Dated: April 14, 2004

Stuart D. Frenkel  
Reg. No. 29,500  
3975 University Drive  
Suite 330  
Fairfax, Virginia 22030  
Teleph ne: (703) 246-9641  
FacsimileL (703) 246-9646

CC:

**STATEMENT UNDER 37 CFR 1.97(e) ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT**

Docket No.  
SDF 02-8

In Re Application Of: Okubo et al.


Serial No.  
10/069,780

Filing Date  
May 3, 2003

Examiner  
Micah Paul Young

Group Art Unit  
1615

Invention: Medicinal Compositions for Oral Use



TO THE ASSISTANT COMMISSIONER FOR PATENTS:

This is a statement under the provisions of 37 CFR 1.97(e) in the above-identified application.

Check applicable statement herebelow:

Statement Under 37 CFR 1.97(e)(1)

- ☐ Each item of information contained in the accompanying Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.

Statement Under 37 CFR 1.97(e)(2)

- ☒ No item of information contained in the accompanying Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned person, after making reasonable inquiry, no item of information contained in the accompanying Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Signature

Dated: April 14, 2004

Stuart D. Frenkel  
Reg. No. 29,500  
3975 University Drive  
Suite 330  
Fairfax, Virginia 22030  
Telephone: (703) 246-9641  
Facsimile: (703) 246-9646

**Certificate of Mailing by First Class Mail**

I certify that this document is being deposited on  
April 14, 2004 with the U.S. Postal Service as first  
class mail under 37 C.F.R. 1.8 and is addressed to the  
Assistant Commissioner for Patents, Washington, D.C.  
20231.


Signature of Person Mailing Correspondence

Stuart D. Frenkel

Typed or Printed Name of Person Mailing Correspondence

cc:

**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)



Docket Number (Optional)  
**SDF 02-8**

Application Number  
**10/069,780**

Applicant(s)  
**Okubo et al.**

Filing Date  
**May 3 2002**

Group Art Unit  
**1615**

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		US 5,369,131	11/29/1994	Poli et al.			

**FOREIGN PATENT DOCUMENTS**

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.